Source of business for IL-23 agents in psoriasis varies across biologic brands. Tremfya’s source of business includes a higher proportion of patients who have previously tried an IL-17 agent before starting an IL-23, as compared to Skyrizi. This finding suggests a preference in the market for Tremfya ahead of Skyrizi after a patient switches from an IL-17 agent.
CRA analytics insight
- A higher proportion of Tremfya patients, versus Skyrizi patients, were previously treated with an IL-17 agent (i.e., Cosentyx or Taltz) prior to trying an IL-23
- A higher proportion of Skyrizi patients were previously treated with a TNF agent compared to Tremfya patients
CRA not only uncovers new trends in data, but delves deeper to illuminate the “why” behind the findings. To learn more, contact Eddie Li and Travis Ruch.
